Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
$0.54
-1.3%
$0.47
$0.13
$3.34
$36.75M0.28977,654 shs254,965 shs
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
$0.50
-11.6%
$0.55
$0.38
$1.60
N/A-0.198,659 shs8,055 shs
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
$0.43
+3.1%
$0.69
$0.39
$4.80
$1.63M0.83202,551 shs25,149 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
+3.81%+0.78%-16.79%+75.69%-80.40%
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
-1.69%-9.97%+38.71%-26.90%-59.85%
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
0.00%+0.26%-57.44%-32.12%-83.97%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
0.4422 of 5 stars
0.03.00.04.70.60.00.6
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/AN/AN/AN/AN/AN/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
2.00
HoldN/AN/A
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/AN/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/A($0.08) per shareN/A
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
$75.69MN/AN/AN/A$6.73 per shareN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/AN/A$11.04 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$17.19M-$0.41N/AN/AN/AN/AN/A-376.40%5/20/2024 (Estimated)
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
-$70.99MN/A0.00N/AN/AN/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
-$4.37M-$7.70N/AN/AN/A-99.74%-60.13%5/9/2024 (Estimated)

Latest CCM, NBSE, BCLI, ARIX, and ANCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/1/2024Q4 2023
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$0.15-$0.11+$0.04-$0.11N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/AN/A
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/AN/AN/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/A
0.24
0.24
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/A
2.87
2.87

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
14.33%
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
12.37%

Insider Ownership

CompanyInsider Ownership
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
5.45%
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
46.50%
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
13.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
2968.34 million64.62 millionOptionable
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
918N/AN/ANot Optionable
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
373.75 million3.23 millionNot Optionable

CCM, NBSE, BCLI, ARIX, and ANCR Headlines

SourceHeadline
NeuBase Therapeutics, Inc.: NeuBase Therapeutics Announces Receipt of Notice from NasdaqNeuBase Therapeutics, Inc.: NeuBase Therapeutics Announces Receipt of Notice from Nasdaq
finanznachrichten.de - April 6 at 8:58 AM
NeuBase Therapeutics Announces Receipt of Notice from NasdaqNeuBase Therapeutics Announces Receipt of Notice from Nasdaq
globenewswire.com - April 5 at 4:05 PM
Once-promising Pittsburgh biotech firm shutting down for goodOnce-promising Pittsburgh biotech firm shutting down for good
technical.ly - March 27 at 8:33 PM
Why Neubase Therapeutics (NBSE) Shares Are NosedivingWhy Neubase Therapeutics (NBSE) Shares Are Nosediving
msn.com - March 27 at 10:32 AM
NeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutics among healthcare moversNeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutics among healthcare movers
msn.com - March 26 at 10:47 AM
Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?
investorplace.com - March 26 at 9:08 AM
NeuBase Therapeutics sets shareholder meeting on dissolution planNeuBase Therapeutics sets shareholder meeting on dissolution plan
bizjournals.com - March 25 at 7:44 PM
NeuBase Therapeutics IncNeuBase Therapeutics Inc
edition.cnn.com - February 26 at 9:46 AM
NeuBase Therapeutics, Inc. (NBSE)NeuBase Therapeutics, Inc. (NBSE)
finance.yahoo.com - February 20 at 1:40 PM
NeuBase Therapeutics Inc (O7P.BE)NeuBase Therapeutics Inc (O7P.BE)
ca.finance.yahoo.com - January 20 at 12:17 AM
Monitoring NeuBase Therapeutics Inc (NBSE) after recent insider movementsMonitoring NeuBase Therapeutics Inc (NBSE) after recent insider movements
knoxdaily.com - January 1 at 2:48 PM
CMU halts licensing agreement with NeuBase TherapeuticsCMU halts licensing agreement with NeuBase Therapeutics
bizjournals.com - December 22 at 7:16 PM
Psychemedics Corporation Appoints Daniella Mehalik as VP - FinancePsychemedics Corporation Appoints Daniella Mehalik as VP - Finance
finance.yahoo.com - November 27 at 10:19 AM
NeuBase Therapeutics Inc NBSENeuBase Therapeutics Inc NBSE
morningstar.com - November 6 at 11:41 PM
NeuBase Therapeutics: Other EventsNeuBase Therapeutics: Other Events
cbonds.com - October 21 at 8:32 AM
NeuBase Therapeutics, Inc. (NBSE.MX)NeuBase Therapeutics, Inc. (NBSE.MX)
finance.yahoo.com - October 6 at 8:56 AM
NeuBase Therapeutics Inc. (NBSE) gets rating Reiterated from H.C. WainwrightNeuBase Therapeutics Inc. (NBSE) gets rating Reiterated from H.C. Wainwright
knoxdaily.com - September 20 at 6:31 PM
Massive Insider Trade At NeuBase TherapeuticsMassive Insider Trade At NeuBase Therapeutics
benzinga.com - September 12 at 3:51 PM
NeuBase falls after largest shareholder disposes of part stakeNeuBase falls after largest shareholder disposes of part stake
msn.com - September 12 at 3:51 PM
NeuBase Therapeutics Issues Statement Regarding Filing By ShareholderNeuBase Therapeutics Issues Statement Regarding Filing By Shareholder
finance.yahoo.com - September 8 at 11:10 AM
Why Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?Why Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?
markets.businessinsider.com - September 6 at 9:07 AM
NBSE’s short interest falls to 41130.0 sharesNBSE’s short interest falls to 41130.0 shares
knoxdaily.com - August 25 at 4:34 PM
Analysts Conflicted on These Healthcare Names: NeuBase Therapeutics (NBSE) and Centessa Pharmaceuticals (CNTA)Analysts Conflicted on These Healthcare Names: NeuBase Therapeutics (NBSE) and Centessa Pharmaceuticals (CNTA)
markets.businessinsider.com - August 16 at 7:45 AM
NeuBase Therapeutics (NASDAQ: NBSE)NeuBase Therapeutics (NASDAQ: NBSE)
fool.com - August 6 at 6:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Brainstorm Cell Therapeutics logo

Brainstorm Cell Therapeutics

NASDAQ:BCLI
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Concord Medical Services logo

Concord Medical Services

NYSE:CCM
Concord Medical Services Holdings Limited, together its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company operates in two segments, Network and Hospital. Its services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, head gamma knife system, and diagnostic imaging services. The company's other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, it provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, the company offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, it operates specialty cancer hospitals, which offer radiotherapy services, diagnostic imaging services, chemotherapy, and surgery. The company was founded in 1997 and is headquartered in Beijing, the People's Republic of China.
NeuBase Therapeutics logo

NeuBase Therapeutics

NASDAQ:NBSE
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.